Induction of altered cellular response to oxidative stress in HT29 colon cancer cells treated with Metformin by Smargiassi, Alberto et al.
IJAE 
Vo l .  120 ,  n .  1  (Supp lem ent) :  69,  2015
© 2015 Firenze University Press 
ht tp://www.fupress .com/ijae
ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY
Induction of altered cellular response to oxidative 
stress in HT29 colon cancer cells treated with Metformin 
Alberto Smargiassi1, Stefano Mancini2, Francesco Cavani1, Marta Benincasa1, Luca Roncucci2, 
Paola Sena1
1 Department of Biomedical, Metabolic and Neural Sciences, Section of Human Morphology, University of 
Modena and Reggio Emilia, Modena, Italy - 2 Department of Diagnostics, Clinical and Public Health Medicine, 
University of Modena and Reggio Emilia, Modena, Italy
Accumulating evidences suggest that Metformin, a biguanide class of anti-diabet-
ic drugs, possesses anti-cancer properties (1). In a number of preclinical and clinical 
studies, Metformin reduced proliferation, induced apoptosis, caused cell cycle arrest, 
and reduced incidence and growth of tumors (2). HT-29 is a human colorectal ade-
nocarcinoma cell line with epithelial morphology and represents a xenograft tumor 
model for colorectal cancer. Nuclear factor E2-related factor 2 (Nrf2) is a transcription 
factor that controls the expression of a large pool of antioxidant and cytoprotective 
genes, regulating the cellular response to oxidative and electrophilic stress. Evidences 
have suggested that mutations in Nrf2 are common in cancer cells, which could help 
tumor cells surviving, and might be associated with poor survival of cancer patients. 
In our study the HT29 cells were treated with graded concentrations of Metformin 
for 24, 48 and 72 hours. We performed immunofluorescence experiments by means 
of confocal microscopy, western blot and cytofluorimetric analysis to evaluate a panel 
of factors involved in apoptotic/autophagic processes and oxidative stress response. 
Our results demonstrate that Metformin exerts growth inhibitory effects on cultured 
HT29 cells by increasing apoptosis and autophagy; moreover, it affects the survival 
of cultured cells inhibiting the transcriptional activation of both Nrf2 and NF-kB. The 
effects of Metformin on HT29 cells were dose dependent as well as time dependent, 
because it has been showed a significant change in the parameters analyzed after 72 
hs versus 24 hs of treatment. Therefore, constitutive activation or augmented signal-
ling of the Nrf2 pathway might be decisive for cell fate during tumorigenesis and 
could affect the response to chemotherapy.
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